Research Fellow (CRISPR)

The UCL Great Ormond Street Institute of Child Health (GOS ICH) The mission of the UCL GOS Institute of Child Health is to improve the health and well-being of children, and the adults they will become, through world-class research, education and public engagement. The UCL GOS ICH, together with its clinical partner Great Ormond Street Hospital for Children, forms the largest concentration of children’s health research outside North America. GOS ICH’s activities include active engagement with children and families, to ensure that our work is relevant and appropriate to their needs. GOS ICH generates the funding for our research by setting out our proposals in high quality applications to public, charitable and industrial funding bodies and disseminates the results of our research by publication in the medical and scientific literature, to clinicians, policy makers and the wider public. The Institute offers world-cla! ss educat ion and training across a wide range of teaching and life learning programmes which address the needs of students and professional groups who are interested in and undertaking work relevant to child health. GOS ICH holds an Athena SWAN Charter Gold Award.

About the role

We are looking for a research assistant to support research projects in the Accelerating Novel Therapies (ANT) Theme of the NIHR GOSH Biomedical Research Centre. Funding for these posts has been made available through the NIHR Great Ormond Street Hospital Biomedical Research Centre (GOSH BRC) ANT Theme. Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH) works in collaboration with its academic partner the UCL Great Ormond Street Institute of Child Health (ICH). Together GOSH and ICH form the GOSH BRC which is the only specialist paediatric Biomedical Research Centre in the UK. The primary research activity of the postholder will be CRISPR gene editing to support iPSC-based! projects modelling human disease in order to develop novel precision therapies. Available immediately and funded for 3 years in the first instance.